Country Club Bank Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Country Club Bank acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 35,777 shares of the medical equipment provider's stock, valued at approximately $4,016,000.

Other large investors also recently made changes to their positions in the company. Garde Capital Inc. bought a new position in shares of Zimmer Biomet during the 1st quarter valued at about $29,000. Menard Financial Group LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $30,000. Washington Trust Advisors Inc. acquired a new position in shares of Zimmer Biomet in the first quarter worth about $30,000. Columbia River Financial Group LLC acquired a new position in shares of Zimmer Biomet in the first quarter worth about $30,000. Finally, Accredited Wealth Management LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $36,000. Institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the transaction, the insider owned 20,424 shares of the company's stock, valued at $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.39% of the stock is owned by company insiders.

Zimmer Biomet Stock Performance

Shares of ZBH traded down $1.27 during trading hours on Friday, reaching $93.88. 1,573,583 shares of the company traded hands, compared to its average volume of 1,825,360. The stock's fifty day moving average is $93.21 and its 200 day moving average is $101.35. The stock has a market cap of $18.57 billion, a P/E ratio of 20.77, a price-to-earnings-growth ratio of 2.20 and a beta of 0.71. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The business had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the prior year, the business earned $1.94 earnings per share. The firm's revenue for the quarter was up 1.1% on a year-over-year basis. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.02%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

Analysts Set New Price Targets

Several research analysts have weighed in on ZBH shares. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. The Goldman Sachs Group decreased their price objective on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Evercore ISI decreased their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday. Raymond James Financial decreased their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Finally, Morgan Stanley decreased their price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $110.00.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.